According to filings with the U.S. Securities and Exchange Commission, NexEos Diagnostics is raising up to $3,000,000.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

About NexEos Diagnostics
NexEos Bio is a privately held medical diagnostics and therapeutics company dedicated to improving the detection, diagnosis, treatment and life-long management of patients living with chronic, eosinophil-related inflammatory diseases. Our Mission is to transform the worlds foremost understanding of eosinophils in human biology into compassionate care solutions for patients through innovative diagnostic and treatment pathways.

To learn more about NexEos Diagnostics, visit https://www.nexeosbio.com/
NexEos Diagnostics Linkedin Page: https://www.linkedin.com/company/nexeos-bio/

Contact:
Stephen Tullman, Chief Executive Officer
610-203-2379
https://www.linkedin.com/in/steve-tullman-4668a518/

SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved.